- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
MALD model helps predict death versus recovery for APAP overdose
A mathematical model that uses laboratory values commonly available on admission can help physicians estimate acetaminophen (APAP: N-acetyl-para-aminophenol) overdose amount, time elapsed since overdose, and potential outcome, according to a study published online February 13 in Hepatology.
A mathematical model that uses laboratory values commonly available on admission can help physicians estimate acetaminophen (APAP: N-acetyl-para-aminophenol) overdose amount, time elapsed since overdose, and potential outcome, according to a study published online February 13 in Hepatology.
Because timely administration of N-acetylcysteine (NAC) to prevent life-threatening liver injury is critical, and patients who overdose on acetaminophen often arrive at the hospital confused or comatose, Christopher H. Remien, University of Utah, Salt Lake City, and colleagues developed the Model for Acetaminophen-induced Liver Damage (MALD).
MALD uses a patient's aspartate aminotransferase, alanine aminotransferase, and international normalized ratio measurements on admission.
“Based on the extent of estimated liver injury, the model predicts death for patients who took over 20g of APAP without NAC administration within the first 24 hours,” the authors said.
Between January 1, 2006, and December 31, 2009, the investigators retrospectively tested the model on 53 patients discharged from the University of Utah.
They found that by using only these initial measurements, the model accurately predicted death versus recovery with 75% sensitivity, 95% specificity. Because the model does not describe kidney damage, the researchers added serum creatinine level in excess of 3.4 mg/dL as an additional criteria. When this value was added, sensitivity increased to 100%.
“Using only data available on admission, the model results fit the post-treatment time series of the markers of liver damage for the majority of individual patients,” the authors wrote. They conclude that the model compares favorably to statistical methods and should be validated in multicentric retrospective and prospective evaluation.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
